UK: New 5-year plan to combat antimicrobial resistance

The national action plan will commit the UK to reducing its use of antimicrobials - such as antibiotics, antifungals, and antivirals - in humans and animals, strengthen surveillance of drug-resistant infections before they emerge, and incentivise industry to develop the next generation of treatments.

The plan will build on progress towards the UK’s 20-year vision for antimicrobial resistance, which will see AMR contained, controlled and mitigated - protecting public health by increasing the risk of disease spread, severe illness, disability and death.

This is the second of a series of 5-year national action plans that will ensure sustained progress by tackling the global threat of AMR.

Learning from the achievements and challenges faced in delivering the previous plan, which was launched in 2019, this new national action plan will run from 2024 to 2029. It embeds lessons from the COVID-19 pandemic and will include specific commitments focusing on infection prevention and control, and the development and use of diagnostics and vaccines.

Action has already been taken across sectors, including the medical and farming industries, to decrease the number of infections and prevent AMR from spreading.

The new plan has 9 strategic outcomes organised under 4 themes:

• Reducing the need for, and unintentional exposure to, antimicrobials - this includes activity to prevent infections arising in the first place (through good infection prevention and control, including vaccination), to monitor the emergence and spread of AMR through strengthened surveillance, and to minimise release of antimicrobials and resistance into the environment.
• Optimising the use of antimicrobials - through ensuring antimicrobials are only used when needed in humans, animals and the environment.
• Investing in innovation, supply and access - by supporting and incentivising the development of new vaccines, diagnostics and therapeutics (including alternatives to antimicrobials), making them accessible to those who need them, and ensuring our work on AMR is informed by cutting edge research.
• Being a good global partner - maintaining the UK’s role as an international leader on AMR and supporting low and middle income countries to respond to the threat of AMR through research, good supply chains and access to antibiotics.